Hosted on MSN20h
Biohaven Just Hurdled An FDA Setback — And Its Moving LinesBiohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback